Anticoagulation Market Growth Dynamics
Direct Oral Anticoagulants (DOACs) have significantly reshaped the Anticoagulation Market. Unlike traditional therapies, DOACs do not require constant blood monitoring and have fewer dietary restrictions, increasing patient convenience and compliance. Drugs like apixaban and rivaroxaban are increasingly prescribed for atrial fibrillation, deep vein thrombosis, and pulmonary embolism. The introduction of DOACs has expanded the patient base, making anticoagulation therapy more accessible and effective. Additionally, these drugs have demonstrated lower risks of intracranial hemorrhage, encouraging broader adoption
. Pharmaceutical companies continue to focus on developing next-generation DOACs with improved safety and efficacy profiles. The integration of digital healthcare solutions for monitoring therapy further enhances patient outcomes, enabling early detection of anomalies and prompt interventions. This shift toward safer and more convenient therapies is a primary driver of the global anticoagulation market, especially in developed countries.